Mineralys Therapeutics, Inc. Operating Income Loss

Quick Answer

Mineralys Therapeutics, Inc. reported Operating Income Loss of -$170.60 million for the year ending 2025.

  • Mineralys Therapeutics, Inc. showed an increase of +11.3% in Operating Income Loss from 2024 to 2025.
  • This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Operating Income Loss has declined by 442.0%.
  • Historical annual values: Fiscal year 2025: -$170.60 million | Fiscal year 2024: -$192.40 million | Fiscal year 2023: -$84.66 million | Fiscal year 2022: -$31.48 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: